AbbVie’s acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, and that makes it worth buying, UBS’ Navin Jacob said Thursday.
AbbVie’s acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, and that makes it worth buying, UBS’ Navin Jacob said Thursday.
blaineonline.finance.blog 